A very powerful medicine which promises to protect the population from HIV (which causes AIDS) is expected to be released in the US after being approved by the US Food and Drug Administration (FDA).

FDA gave the ‘green light’ to the drug Yeztugo (use of Lenakapavir) by Gilead Sciences.

The company promises that, with two injections a year – One semester – the population will be protected against the virus.

Based on clinical trials, Yeztugo “kept” 99.9% of participants who received it negative to HIV.

Daniel O’Day, President and CEO of Gilead, spoke of a “landmark moment” in the ten -year battle against HIV. ”

“Yeztugo will help us prevent HIV on a scale we have never seen before. Now we have a way to end the HIV epidemic once and for all, “he said in a press release.

The injectable solution of Lenakapavir acts as a ‘vaccine’ and addressed to people over 12 years of age.

In fact, it is the first drug to prevent HIV to be taken only twice a year.

Dr. Barton Ford Haynes told CBS News that Lenakapavir is a “wonderful development for the sector”, though – as she points out – there is still a need for a vaccine.

Although the manufacturer Gilead Sciences has not announced a price for the new drug, analysts estimate that price in the US could reach the $ 25,000 annuallye.